Analysis of the Reporting of Adverse Drug Reactions in Children and Adolescents in Germany in the Time Period from 2000 to 2019

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 Mar 3

PMID 33657139

Citations 8

Authors

Sarah Leitzen

Diana Dubrall

Irmgard Toni

Julia Stingl

Maike Schulz

Matthias Schmid

Antje Neubert

Bernhardt Sachs

Affiliations

Soon will be listed here.

Abstract

The objective of this study was to analyse reports on adverse drug reactions (ADRs) from Germany in the particularly vulnerable patient group of children and adolescents. Reporting characteristics, demographic parameters and off-label use were examined among others. The ratio of ADR reports per number of German inhabitants and the ratio of ADR reports per number of German inhabitants exposed to drugs were calculated and compared. These parameters were examined to derive trends in reporting of ADRs. 20,854 spontaneous ADR reports for the age group 0-17 years were identified in the European ADR database EudraVigilance for the time period 01.01.2000-28.02.2019 and analysed with regard to the aforementioned criteria. 86.5% (18,036/20,854) of the ADR reports originated from Healthcare Professionals and 12.2% (2,546/20,854) from non-Healthcare Professionals. 74.4% (15,522/20,854) of the ADR reports were classified as serious. The proportion of ADR reports per age group was 11.8% (0-1 month), 11.0% (2 months-1 year), 7.4% (2-3 years), 9.3% (4-6 years), 25.8% (7-12 years), and 34.8% (13-17 years) years, respectively. Male sex slightly dominated (51.2% vs. 44.8% females). Only 3.5% of the ADR reports reported off-label use. The annual number of ADR reports increased since 2000, even if set in context with the number of inhabitants and assumed drug-exposed inhabitants. The pediatric population declined in the study period which argues against its prominent role for the increase in the total number of ADR reports. Instead, among others, changes in reporting obligations may apply. The high proportion of serious ADR reports underlines the importance of pediatric drug safety.

Citing Articles

Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs.

Raicevic B, Belancic A, Mirkovic N, Jankovic S Pharmacol Res Perspect. 2025; 13(2):e70080.

PMID: 39995024 PMC: 11850437. DOI: 10.1002/prp2.70080.

Adverse Event Profile of First-line Drugs for Treating Patent Ductus Arteriosus in Neonates: A Disproportionality Analysis Study of USFDA Adverse Event Reporting System.

Sridharan K, Sivaramakrishnan G Paediatr Drugs. 2024; 26(6):767-785.

PMID: 39367998 DOI: 10.1007/s40272-024-00657-3.

Safety Monitoring of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years by Using EudraVigilance Pharmacovigilance Database: The CoVaxChild Study.

Zinzi A, Gaio M, Liguori V, Ruggiero R, Tesorone M, Rossi F Vaccines (Basel). 2023; 11(2).

PMID: 36851276 PMC: 9962857. DOI: 10.3390/vaccines11020401.

Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review.

Makhene N, Steyn H, Vorster M, Lubbe M, Burger J Ther Adv Drug Saf. 2023; 14:20420986221143272.

PMID: 36713000 PMC: 9880583. DOI: 10.1177/20420986221143272.

Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.

Pozsgai K, Szucs G, Konig-Peter A, Balazs O, Vajda P, Botz L Front Pharmacol. 2022; 13:964399.

PMID: 36147337 PMC: 9485933. DOI: 10.3389/fphar.2022.964399.

References

Ferrajolo C, Capuano A, Trifiro G, Moretti U, Rossi F, Santuccio C . Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001 - 2012. Expert Opin Drug Saf. 2014; 13 Suppl 1:S9-20. DOI: 10.1517/14740338.2014.939581. View

Aagaard L, Nielsen L, Hansen E . Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf. 2009; 32(11):1067-74. DOI: 10.2165/11316680-000000000-00000. View

Bourgeois F, Murthy S, Pinto C, Olson K, Ioannidis J, Mandl K . Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012; 130(2):285-92. PMC: 3408692. DOI: 10.1542/peds.2012-0139. View

Gore R, Chugh P, Tripathi C, Lhamo Y, Gautam S . Pediatric Off-Label and Unlicensed Drug Use and Its Implications. Curr Clin Pharmacol. 2017; 12(1):18-25. DOI: 10.2174/1574884712666170317161935. View

Wimmer S, Neubert A, Rascher W . The Safety of Drug Therapy in Children. Dtsch Arztebl Int. 2016; 112(46):781-7. PMC: 4671328. DOI: 10.3238/arztebl.2015.0781. View

Johann-Liang R, Wyeth J, Chen M, Cope J . Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007. Pharmacoepidemiol Drug Saf. 2008; 18(1):24-7. DOI: 10.1002/pds.1679. View

Knopf H, Sarganas G, Grams D, Du Y, Poethko-Muller C . [Application of medicines and nutritional supplements in childhood and adolescence in Germany : Results from KiGGS Wave 2]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019; 62(10):1215-1224. DOI: 10.1007/s00103-019-03008-7. View

Knopf H, Wolf I, Sarganas G, Zhuang W, Rascher W, Neubert A . Off-label medicine use in children and adolescents: results of a population-based study in Germany. BMC Public Health. 2013; 13:631. PMC: 3706213. DOI: 10.1186/1471-2458-13-631. View

Dubrall D, Schmid M, Alesik E, Paeschke N, Stingl J, Sachs B . Frequent Adverse Drug Reactions, and Medication Groups under Suspicion. Dtsch Arztebl Int. 2018; 115(23):393-400. PMC: 6041966. DOI: 10.3238/arztebl.2018.0393. View

10.

Carnovale C, Brusadelli T, Zuccotti G, Beretta S, Sullo M, Capuano A . The importance of monitoring adverse drug reactions in pediatric patients: the results of a national surveillance program in Italy. Expert Opin Drug Saf. 2014; 13 Suppl 1:S1-8. DOI: 10.1517/14740338.2014.928692. View

11.

Hazell L, Shakir S . Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006; 29(5):385-96. DOI: 10.2165/00002018-200629050-00003. View

12.

Oehme A, Rashed A, Hefele B, Wong I, Rascher W, Neubert A . Adverse drug reactions in hospitalised children in Germany are decreasing: results of a nine year cohort-based comparison. PLoS One. 2012; 7(9):e44349. PMC: 3445603. DOI: 10.1371/journal.pone.0044349. View

13.

Star K, Noren G, Nordin K, Ralph Edwards I . Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf. 2011; 34(5):415-28. DOI: 10.2165/11587540-000000000-00000. View

14.

Joseph P, Craig J, Caldwell P . Clinical trials in children. Br J Clin Pharmacol. 2013; 79(3):357-69. PMC: 4345947. DOI: 10.1111/bcp.12305. View

15.

Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salje K, Mueller S . Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011; 20(6):626-34. DOI: 10.1002/pds.2118. View

16.

Magalhaes J, Rodrigues A, Roque F, Figueiras A, Falcao A, Herdeiro M . Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review. Eur J Clin Pharmacol. 2014; 71(1):1-13. DOI: 10.1007/s00228-014-1768-9. View

17.

Aldea A, Garcia Sanchez-Colomer M, Fernandez Quintana E, Garcia Saiz M . Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. Eur J Clin Pharmacol. 2012; 68(9):1329-38. DOI: 10.1007/s00228-012-1255-0. View

18.

van den Anker J, Reed M, Allegaert K, Kearns G . Developmental Changes in Pharmacokinetics and Pharmacodynamics. J Clin Pharmacol. 2018; 58 Suppl 10:S10-S25. DOI: 10.1002/jcph.1284. View

19.

Dubrall D, Just K, Schmid M, Stingl J, Sachs B . Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices. BMC Pharmacol Toxicol. 2020; 21(1):25. PMC: 7092423. DOI: 10.1186/s40360-020-0392-9. View

20.

Mittmann N, Knowles S, Gomez M, Fish J, Cartotto R, Shear N . Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf. 2004; 27(7):477-87. DOI: 10.2165/00002018-200427070-00004. View